Fisher & Paykel share price on watch following FY21 trading update

The Fisher & Paykel share price could be on watch following the release of its FY21 trading update. Strong demand for its products continue.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price could be on the move today, following the release of the company's FY21 trading update.

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems used for use in chronic and acute respiratory care, surgery and treatment of obstructive sleep apnea. The company's products are sold worldwide. 

Trading update

Strong demand has continued for the company's hospital respiratory care products due to the ongoing spread of the coronavirus pandemic around the world. 

For the first 4 months of the company's financial year to the end of July 2020, hospital hardware sales have increased with 390% constant currency revenue growth compared to the prior comparable period (pcp). Additionally, hospital consumables revenue has grown 48% and overall hospital product group revenue has grown 91% compared to the pcp and in constant currency terms. 

Global sales of invasive ventilation and Optiflow consumables in July have returned to similar levels seen in April. Revenue in geographic areas is being impacted by the amount of infections. More than half of Fisher & Paykel's Airvo (humidified high flow system) hardware sales are outside North America and Europe this financial year. 

Constant currency revenue growth in obstructive sleep apena (OSA) for the first 4 months of FY21 was 4% compared to pcp. The growth in home respiratory support is more than offsetting a decline in OSA flow generators. Homecare revenue growth is 5% in constant currency terms compared to the pcp.

Outlook

Significant uncertainty about the extent and duration of the impact of the coronavirus has led Fisher & Paykel to make some assumptions regarding its FY21 results.

The assumptions include global hospitalisations requiring respiratory support to steadily return normal by the end of the calendar year and countries around the world continue to build respiratory care infrastructure. Additionally, it is assuming sleep apnea diagnosis rates are reduced for the year and freight costs remain elevated, resulting in a 200 basis points reduction in gross margin in constant currency for the year.

 "On this basis and at current exchange rates, full year operating revenue for the 2021 financial year would be approximately NZ$1.61 billion and net profit after tax would be approximately NZ$365 million to NZ$385 million" said Managing Director and CEO Lewis Gradon.

About the Fisher & Paykel share price

In its FY20 results released to the market on 29 June 2020, operating revenue was NZ$1.26 billion and net profit after tax was NZ$287.3 million.

The Fisher & Paykel share price has been a major beneficiary from the demand for its products during the coronavirus pandemic. As a result, its share price has surged 111.42% in the past year and is currently trading at $31.84.

Motley Fool contributor Matthew Donald has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ASX Share Market News

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a lacklustre start to the trading week this Monday.

Read more »

A woman smiles at the outlook she sees through binoculars.
Broker Notes

Buy, hold, sell: Newmont, Stockland, NAB shares

Let's check out some new expert recommendations.

Read more »

Surprised child reading all about ASX 200 shares in a newspaper.
ASX Share Market News

Why is everyone talking about DroneShield, Treasury Wine and Westpac shares on Monday?

DroneShield, Westpac, and Treasury Wine shares are turning heads on Monday. But why?

Read more »

Red sell button on an Apple keyboard.
Broker Notes

Sell alert! Why this expert is calling time on Whitehaven and Beach Energy shares

A leading analyst forecasts mounting headwinds for Whitehaven and Beach Energy shares. But why?

Read more »

Invest written on a notepad with Australian dollar notes and piggybank.
ASX Share Market News

BOQ launches $295m capital return and special dividend in FY26 update

Bank of Queensland returns $295 million to shareholders and finalises transformational milestones in its latest capital and earnings update.

Read more »

Two playful kangaroos relaxing on a beach.
Opinions

2 strong Australian stocks to buy now with $9,000

These businesses have strong return potential…

Read more »

A group of stockbrokers sit in a room with several computer screens in front of them as they discuss the Zip share price and Zip's merger with Sezzle
Broker Notes

Buy, hold, sell: WiseTech, Whitehaven, AMP shares

Let's start the week with some fresh ratings from the experts. 

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Broker Notes

How high does Macquarie think Resmed shares will go?

The hearing device company looks undervalued, according to the Macquarie team.

Read more »